Please assess the completion status of the following clinical trial:

Trial Title: MISOBEST - Orally Misoprostol Solution (Cytotec®) Versus Orally Misoprostol as a Tablet (Angusta®) for Induction of Labor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Singleton gestations~* Cephalic presentation~* ≥37-42+0 weeks of gestation~* Unfavorable cervix score BS \<6 in nulliparous women and \<5 in parous women~* All participating women in the studies will receive oral and written information and must give informed consent before participation~Exclusion Criteria:~1. Inability to understand the study information written in Swedish or English~2. Previous hysterotomy (scar in the uterine myometrium)~3. Non-reassuring cardiotocography (CTG) on admission (the door-test, first 20 minutes of registration of CTG).~4. Hypersensitivity to the active substance~5. If active labor has started~6. When oxytocin infusion is already used~7. Placenta previa~8. Renal failure (GFR \<15 ml/min/1.73 m2).~9. Any condition or circumstance due to which the investigator considers it is not in the best interest of subject to participate in the study or the inclusion of a subject risks negatively impacting the scientific or ethical integrity of the clinical trial.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Cytotec® (Type: EXPERIMENTAL): IOL with misoprostol oral solution (Cytotec®) 25 ug every second hour, up to eight doses, or until painful contractions are obtained. Thereafter IOL will proceed according to clinical practice.
- Angusta® (Type: ACTIVE_COMPARATOR): IOL with misoprostol oral tablets (Angusta®) 25 ug every second hour, up to eight doses, or until painful contractions are obtained. Thereafter IOL will proceed according to clinical practice.

Based on this trial design, predict the completion outcome and termination type (if applicable).